The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
about
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
P2860
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
@en
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
@nl
type
label
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
@en
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
@nl
prefLabel
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
@en
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
@nl
P2860
P356
P1476
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.
@en
P2093
Elvira Pelosi
P2860
P304
P356
10.1155/2013/275760
P50
P577
2013-07-09T00:00:00Z